ACADIA Pharmaceuticals Inc. projects strong commercial growth, forecasting approximately $1.7 billion in global net sales by 2028. The company expects NUPLAZID to contribute around $1 billion and DAYBUE approximately $700 million to this total. This outlook reflects significant momentum in both products and underscores the company's expectations for sustained business performance growth over the period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113614282) on January 13, 2026, and is solely responsible for the information contained therein.
Comments